ZYDUS WELLNESS LTD.-$ - 531335 - Clarification sought from Zydus Wellness Ltd
The Exchange has sought clarification from Zydus Wellness Ltd with respect to news article appearing on https://www.business-standard.com dated April 15, 2022 titled "SEC approves two-dose regimen of Zydus Covid-19 vaccine ZyCoV-D".The reply is awaited.
Zydus Lifesciences receives USFDA approval for generic product
Zydus Lifesciences said the group now has 331 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in FY 2003-04.
SEC approves two-dose regimen of Zydus' Covid-19 vaccine ZyCoV-D
Zydus to conduct mixing trials to test vax efficacy after two shots of Covishield/Covaxin ZYDUS WELLNESS LTD.-$ - 531335 - Intimation Of Certificate Under Regulation 40(10).
Intimation of Certificate under Regulation 40(10). ZYDUS WELLNESS LTD.-$ - 531335 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayZYDUS WELLNESS LTD.- 2CINL15201GJ1994PLC023490 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Dhanraj P Dagar Designation: Company Secretary and Compliance Officer EmailId: dhanraj.dagar@zyduswellness.com Name of the Chief Financial Officer: Umesh V Parikh Designation: Chief Financial Officer EmailId: umesh.parikh@zyduswellness.com Date: 09/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Buy Zydus Lifesciences: target of Rs 480: Sharekhan
Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 480 in its research report dated April 07, 2022. ZYDUS WELLNESS LTD.-$ - 531335 - Shareholding for the Period Ended March 31, 2022
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2022. For more details, kindly Click here ZYDUS WELLNESS LTD.-$ - 531335 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Dhanraj P DagarDesignation :- Company Secretary and Compliance Officer ZYDUS WELLNESS LTD.-$ - 531335 - Compliance Certificate Under Regulation 7(3).
nse-frontend-navigation (nseindia.com) ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Certificate under Regulation 74(5).